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Abstract
Background Live donor nephrectomy is a safe procedure. However, long-term donor prognosis is debated, necessitating 
high-quality studies.
Methods A follow-up study of 761 living kidney donors was conducted, who visited the outpatient clinic and were propensity 
score matched and compared to 1522 non-donors from population-based cohort studies. Primary outcome was kidney func-
tion. Secondary outcomes were BMI (kg/m2), incidences of hypertension, diabetes, cardiovascular events, cardiovascular 
and overall mortality, and quality of life.
Results Median follow-up after donation was 8.0 years. Donors had an increase in serum creatinine of 26 μmol/l (95% CI 
24–28), a decrease in eGFR of 27 ml/min/1.73 m2 (95% CI − 29 to − 26), and an eGFR decline of 32% (95% CI 30–33) 
as compared to non-donors. There was no difference in outcomes between the groups for ESRD, microalbuminuria, BMI, 
incidence of diabetes or cardiovascular events, and mortality. A lower risk of new-onset hypertension (OR 0.45, 95% CI 
0.33–0.62) was found among donors. The EQ-5D health-related scores were higher among donors, whereas the SF-12 physi-
cal and mental component scores were lower.
Conclusion Loss of kidney mass after live donation does not translate into negative long-term outcomes in terms of morbid-
ity and mortality compared to non-donors.
Trial registration Dutch Trial Register NTR3795.
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Introduction
Each year, nearly 5000 healthy individuals in Europe and 6000 
in the United States donate a kidney to help patients with end-
stage renal disease (ESRD) [1, 2]. Potential living donors are 
extensively screened by transplant professionals, who select 
only those donors whose health is unlikely to be compromised 
by donation. The surgical donation procedure has been dem-
onstrated to be safe with a low risk of peri-operative morbidity 
and a very low risk of procedure-related mortality [3, 4]. How-
ever, donors should be aware of the implications of donation 
in their future life. Compared to pre-donation levels, eGFR 
initially decreases after donation [5] but seems to remain stable 
with no further decrease after more than a decade [6, 7].
Recently, unfavorable results from donor versus non-donors 
studies have emerged. Previously, it was assumed that donors 
have no increased risk of mortality [4, 8–10], ESRD [8, 
11–13], or gestational hypertension [8, 14] compared to non-
donors. However, recent single-center and national registry 
studies on long-term follow-up outcomes comparing donors to 
non-donors have reported an increased risk of mortality [15], 
ESRD [15–17], gestational hypertension, and pre-eclampsia 
[18] among donors.
Determining the long-term impact of living donation is 
essential and criteria are needed to identify the donors at risk 
in the long-term. Current literature presents conflicting results 
regarding safety of live kidney donors at follow-up, in which 
the flaw of comparability of studied donors and matched non-
donors is key to these conflicting results [19]. Therefore a 
more accurate selection of non-donors is necessary. Further-
more, low absolute risk among donors creates uncertainty in 
estimates when adjusting for potential confounders [19]. It is 
important that comprehensive data become available for this 
process to strive for a similar health status between donors and 
non-donors, allowing proper analysis of the donation proce-
dure with regard to risk factors. The safety of these healthy 
individuals who are not patients themselves is paramount and 
demand more data to validate live kidney donation on the long-
term. In the present study, we aim to overcome limitations of 
previous studies by comparing donors to non-donors using 
propensity score matching to evaluate the long-term effects 
on serum creatinine and eGFR as well as outcomes, including 
hypertension, diabetes mellitus, cardiovascular events, sur-
vival, and quality of life.
Materials and methods
Study design
The conduct and reporting of the study followed STROBE 
guidelines for observational studies [20] (Supplemental 
Table S1). The study was designed by the authors [21] and 
approval obtained by the medical ethics committee of Eras-
mus University Medical Center, Rotterdam, the Netherlands 
(MEC-2012-519). Informed consent was obtained from all 
study participants. We initiated a propensity-score matched 
follow-up study using individual level donor data from 
Erasmus University Medical Center, and comparison data 
from two population-based follow-up studies. All eligible 
donors were invited for an extensive study visit that included 
self-reported medical history, and an interview-based ques-
tionnaire on quality of life, supplementary to their annual 
physical examination and laboratory tests. The study visits 
were conducted between August 19, 2013, and December 
31, 2014. To increase the response among donors, the visits 
were also conducted at Radboud University Medical Center 
in Nijmegen and Admiraal de Ruyter Hospital in Goes in dif-
ferent provinces of the Netherlands. Donors were included in 
the study if they were still alive during the inclusion period, 
lived in the Netherlands, and visited one of the study hospi-
tals or filled out self-report forms. All questionnaire-related 
interviews were conducted by one of the three investigators. 
Subjects who declined to participate were asked to fill out 
self-report forms on their medical history and quality of life 
and permission was requested for access to their medical 
records in order to analyze potential selection bias.
Data sources
All data were obtained from self-reporting and interview-
based questionnaires, physical examination, and laboratory 
tests. To ensure the accuracy and completeness of the donor 
data, we manually reviewed the pre-donation and annual 
follow-up medical records in the hospital’s electronic patient 
database. We also obtained information from three linked 
databases containing the municipal administration records 
on vital status and demographic characteristics for all inhab-
itants, and the registry for dialysis patients. Outcome data 
were complete for all variables in this study except for qual-
ity of life scores among non-donors.
Population
Donors
We included all individuals who donated a kidney from 
1981 through 2010 at the Department of Surgery of Eras-
mus University Medical Center or who had their full medical 
work-up performed there prior to donation but donated at 
another transplant center because of their participation in 
the national kidney exchange transplant program. [22] We 
identified 1092 donors eligible for this study (See Supple-
mental Figure S1 for an overview of the number of donations 
per year).
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Non‑donors
Inhabitants of Western Europe have similar donation and 
transplantation legislation, lifestyles, and healthcare systems 
and access. [23–25] Therefore, non-donors were selected 
from the Study of Health in Pomerania (SHIP) [26] in Ger-
many, a population-based cohort study with participants 
aged 20–70 years, and the Rotterdam Study [27] in the Neth-
erlands, a population-based cohort study with participants 
aged 45 years and older. SHIP is a population-based cohort 
study initiated in 1997 among inhabitants of West Pomerania 
in the north-east of Germany. Two main objectives of this 
study were first to assess prevalence and incidence of com-
mon risk factors, subclinical disorders and clinical diseases, 
and second to investigate the complex associations among 
these. The Rotterdam Study is a prospective cohort study 
that started in 1990 in Ommoord, a district of the city of Rot-
terdam, the Netherlands. The study analyzes determinants 
of cardiovascular, endocrine, hepatic, neurological, ophthal-
mic, psychiatric and respiratory diseases. Both population-
based studies were selected to cover the whole age range 
of our donors. Participants from the SHIP-0 cohort who 
enrolled between 1997 and 2001 (n = 4308) were selected 
based on sufficient follow-up time. Participants from the 
Rotterdam Study II and III cohorts who enrolled between 
2000 and 2001 or 2006 and 2008 respectively (n = 6943), 
were selected since cohort I did not included all studied out-
comes at baseline. Data were taken from the latest follow-up 
examinations of both cohorts, 2012 for the SHIP and 2015 
for the Rotterdam Study.
Study outcomes
All study subjects were followed until death, emigration 
out of the country, or the end of the examination period 
(April 20, 2016, for donors, and December 31, 2015, for 
non-donors). The primary outcome was serum creatinine 
(μmol/l) and eGFR (ml/min/1.73 m2; calculated using the 
CKD-EPI formula [28]), which was measured at baseline, 
one year after donation (donors only), and at long-term 
follow-up. ESRD was defined as necessitating dialysis or 
transplantation. Secondary outcomes were incidence of 
hypertension (defined as use of antihypertensive medica-
tion, systolic blood pressure ≥ 140 mmHg, or diastolic blood 
pressure ≥ 90 mmHg), incidence of diabetes (defined as use 
of antidiabetic medication or glucose ≥ 7 mmol/l with diet), 
BMI (kg  m2), incidence of cardiovascular events (defined 
as myocardial infarction, percutaneous coronary interven-
tion, coronary artery bypass surgery, or cerebral vascular 
accident), cardiovascular mortality (defined as death by car-
diovascular event), mortality (censor date April 20, 2016, 
for donors; December 31, 2012 for the SHIP; and Decem-
ber 31, 2015, for the Rotterdam Study), and quality of life 
measured by ShortForm-12 (SF-12) [29] and EuroQoL (EQ-
5D) [30]. Both quality of life questionnaires were used since 
the Rotterdam Study only included the EuroQoL and SHIP 
the ShortForm-12. The Short Form health questionnaire 
is a validated and commonly used tool to measure health 
related quality of life ranging from a score between 0 and 
100. It contains questions on physical performance and well-
being, and mental functioning and emotional well-being, 
resulting in the physical (PCS) and mental component score 
(MCS) respectively. The EQ-5D records quality of life in 
five dimensions: mobility, self-care, daily activities, pain or 
discomfort, and anxiety/depression. The responses on the 
five dimensions combine to a score according to Dutch tariff 
[31] between − 0.59 (worst imaginable health state) and 1.00 
(best imaginable health state).
Propensity score matching
Restriction, multiple imputation, and matching were used to 
select a cohort of non-donors that was just as healthy as the 
donors (Supplemental Methods). We restricted the sample 
of all Rotterdam Study and SHIP participants (n = 11,251) 
to eligible non-donors without identified contraindications 
for donation (n = 9270) at the time of enrollment in the pop-
ulation-based cohort studies, including pre-existing diabe-
tes, an estimated glomerular filtration rate (eGFR) < 60 ml/
min/1.73  m2 (defined by blood or urine analysis), and 
BMI > 40 kg/m2. To account for the fact that the data on 
covariates at baseline were not complete for all subjects, a 
multiple imputation approach was utilized to impute missing 
covariate values based on the method of chained equations 
[32]. Using this procedure, 20 complete data sets were cre-
ated. For each imputed data set, non-donors were matched 
to donors with replacement using propensity score matching 
[33, 34]. Balance between the donor and non-donor groups 
was checked with summary measures of Q–Q plots com-
paring the covariates in the matched groups [35]. Initially, 
a 4:1 match was targeted [21], but the ratio was reduced to 
2:1 to allow for optimal balance. Matching was based on 
baseline characteristics of age (years), gender, year of dona-
tion/enrollment in the population-based cohort study, weight 
(kg), height (cm), ethnicity, eGFR (ml/min/1.73 m2), systolic 
and diastolic blood pressure (mmHg), pre-existing hyperten-
sion, pre-existing cardiovascular events, serum glucose level 
(mmol/l), current smoking, alcohol use, and education level.
Statistical analysis
Baseline characteristics were compared using the 
Kruskal–Wallis test for continuous variables and the Fish-
er’s exact test for dichotomous variables, without account-
ing for matching. All analyses were performed for each of 
the complete data sets and the results from the analysis of 
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each imputed data combined using Rubin’s formulas [36]. 
The analyses of continuous outcomes were based on linear 
regression, the analyses of dichotomous outcomes on logis-
tic regression, and the analysis of survival on Cox regres-
sion with adjusted standard errors accounting for matching 
and the fact that 103 non-donors were matched twice. For 
each regression analysis we tested for differences between 
donors and non-donors while also correcting for the covari-
ates age, gender, start year (date of donation or enrollment in 
population-based study), education level, pre-existing hyper-
tension, baseline serum creatinine, and baseline eGFR, as 
well as weight, height, alcohol use, and smoking status at 
follow-up. To evaluate potential effect modification, inter-
actions were tested by age, gender, and follow-up duration 
in the final multivariate model of creatinine and eGFR. The 
results were not corrected for multiple testing.
Results
Characteristics of the study participants
Between 1981 and 2011, a total of 1092 live kidney dona-
tions were performed at our center and all donors were eli-
gible for inclusion. A total of 761 donors were matched with 
non-donors, including 705 who visited the outpatient clinic 
(Fig. 1). The donors comprised 429 living-related (54.1%) 
and 332 living-unrelated (45.9%) live kidney donations. 
The median follow-up time for donors was 8.0 (5.1–11.9) 
years. Non-donors from the Rotterdam Study and SHIP were 
included; a total of 11,251 individuals participated in these 
population-based cohort studies. After applying our exclu-
sion criteria, 9270 non-donors were eligible for 2:1 match-
ing, resulting in 1522 non-donors being included in the study 
(54% from the Rotterdam Study and 46% from SHIP). The 
median follow-up time for non-donors was 7.0 (5.4–10.9) 
years. Age, baseline systolic blood pressure, ethnicity, and 
education were significantly different between donors and 
non-donors (Table 1).
Effect of donation on kidney function
In the donor population, baseline eGFR was 92.6  ml/
min/1.73  m2 (IQR 79.8–103.8  ml/min/1.73 m2), one-
year eGFR was 59.0 ml/min/1.73 m2 (IQR 50.5–68.6 ml/
min/1.73 m2), and median eGFR at follow-up after 8 years 
59.9  ml/min/1.73  m2 (IQR 51.4–70.7  ml/min/1.73  m2) 
(Fig.  2). The serum creatinine levels for donors were 
77.0 μmol/l (IQR 68.0–87.0 μmol/l) at baseline, 106.0 μmol/l 
(IQR 93.0–121.0 μmol/l) at one-year and 100.0 μmol/l (IQR 
87.5–114.0) μmol/l at 8-year follow-up. Sixteen donors 
(2.4%) and 10 non-donors (1.2%) developed microalbuminu-
ria (p = 0.09). These donors had a median eGFR of 57.9 ml/
min/1.73 m2 (IQR 47.7–68.2 ml/min/1.73 m2) and median 
serum creatinine of 99.5 μmol/l (IQR 86.1–112.9 μmol/l) at 
follow-up. Two donors (0.3%) developed ESRD.
Primary outcomes
In donors, serum creatinine was significantly higher 
(+26.03 μmol/l (95% CI 24.17; 27.89)) and the eGFR sig-
nificantly lower (− 27.23 ml/min/1.73 m2 (95% CI − 28.61; 
− 25.85)) compared to non-donors. The eGFR declined 31.7 
percent (95% CI 29.9; 33.5) more among donors than non-
donors (all p < 0.001, Table 2). The incidence of ESRD was 
not significantly different between donors and non-donors 
(OR 0.56, 95% CI 0.19; 1.71).
Secondary outcomes
The crude incidence for secondary outcomes among donors 
was 5.2% for new-onset diabetes, 39.2% for new-onset 
hypertension, 3.9% for cardiovascular events, 0.1% cardio-
vascular mortality, and 1.2% for overall mortality.
Secondary outcomes showed no significant differences 
between donors and non-donors for BMI (0.02, (95% CI 
− 0.04; 0.07), incidence of diabetes (OR 1.14, 95% CI 0.71; 
1.84), cardiovascular events (OR 1.06, 95% CI 0.64; 1.74), 
and cardiovascular mortality (OR 0.13, 95% CI 0.01; 1.24). 
A significantly lower risk of developing new-onset hyper-
tension (OR 0.45, 95% CI 0.33; 0.62) and overall mortality 
(OR 0.06, 95% CI 0.05; 0.08) was found among donors. 
Of the entire 1981–2010 donor population (n = 1092), 80 
donors died, including 38 due to cancer and 15 due to a 
cardiovascular event.
Quality of life
The health-related quality of life score was significantly 
higher among donors with 0.06 higher score for EQ-5D 
(95% CI 0.05; 0.08 on a scale of − 0.59 to 1.00). The SF-12 
physical and mental component scores were both signifi-
cantly lower among donors: − 1.36 (95% CI − 2.38; − 0.33) 
and − 4.61 (95% CI − 5.75; − 3.47), respectively, on a scale 
of 0–100.
Discussion
In this European study of live kidney donors and propensity 
score matched non-donors from the general population, we 
demonstrated that the long-term prognosis of people that 
underwent a live kidney donation is identical to non-donors. 
Moreover, the lower eGFR after donation due to reduction 
of parenchymal kidney volume did not result in a higher 
incidence of ESRD, cardiovascular disease or mortality 
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compared to non-donors. This study adds to the current lit-
erature, because it suggests that recently reported negative 
outcomes of kidney donation may partially be explained by 
the selection of the non-donor control group. This confirms 
our recent methodological assessment of previous studies 
analyzing long-term safety of live kidney donation [19].
As expected, eGFR among donors was decreased at fol-
low-up as compared to the general population (Table 2). The 
decrease in eGFR is likely attributable to the donation proce-
dure, since the eGFR declined in the first year after donation 
and remained stable thereafter. Thus, this eGFR-loss likely 
reflects the loss of nephron mass after donation. However, 
eGFR in donors should be interpreted carefully and may 
deviate substantially from measured GFR. For example, 
Tan et al. compared CKD-EPI GFR with measured GFR 
using iothalamate in 64 kidney donors [37]. They showed 
that more than half of kidney donors had eGFR < 60 ml/
min/1.73  m2, whereas only 25% had a measured GFR 
below this level. This misclassification mainly affected 
donors > 55 years. This implies that the true GFR in our 
cohort of kidney donors may be better than estimated by the 
CKD-EPI equation.
In a recent published systematic review and meta-analysis 
comparing mid- and long-term health risks in living kid-
ney donors and matched non-donors [38] the outcomes for 
eGFR, creatinine, all-cause mortality, cardiovascular events, 
the incidence of type 2 diabetes, and health-related quality 
of life as measured with the Short-Form 12 among donors 
were similar to our findings. As opposed to their results, 
our study had a lower risk of hypertension and no increased 
risk for ESRD. This may be explained by our annual outpa-
tient follow-up appointments in which blood pressure and 
Fig. 1  Flowchart of inclusion in the live kidney donor process
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blood- and urine analysis are performed and abnormalities 
could be detected early. Although we found a statistically 
significant difference in the SF-12 physical and mental com-
ponent scores, the difference between donors and non-donors 
was < 5-points which is not deemed clinically relevant [29]. 
In contrast, a higher EuroQoL score was seen among donors. 
This can be explained since a previous study has found that 
when indicating a health problem on the EQ-5D a signifi-
cantly lower mean SF-12 component scores for all dimen-
sions is found [39]. Therefore, these at first sight contrasting 
results should not be seen as a contradiction.
Several studies on live kidney donation have used a 
similar comparison design with matched non-donors and 
reported similar outcomes in overall mortality and cardio-
vascular events [4, 8, 10]. However, others have reported 
contradicting results [15, 40]. This may be explained by 
differences in study design, questioning the comparability 
of donors and non-donors and the reliability of the results 
[19]. Live kidney donors are healthy individuals and submit-
ting them to a surgical procedure stretches the Hippocratic 
oath taken by physicians. Therefore, prior to donation, a 
well-balanced decision has to be taken regarding the suit-
ability and the risk estimation for donation. By extensively 
screening donors the healthiest individuals are selected, 
which may limit the comparability with a general selection 
of non-donors. Comparing donors to a general selection of 
the background population can underestimate risks added by 
the donation [9]. Matching donors to selective non-donors 
with similar baseline health status, as was done in this study, 
can overcome this limitation. We have added these factors 
to our study design by matching and adjusting for multiple 
health characteristics. Thus, this study aimed to include rep-
resentative non-donors in Western populations. Although at 
first sight age, ethnicity and systolic blood pressure were sta-
tistically different between donors and non-donors, a closer 
look at the actual difference are thought to be negligible 
when advising potential donors by transplant professionals. 
Table 1  Baseline characteristics 
of included live kidney donors 
at the time of donation and 
matched nondonors at the time 
of enrolment in population 
based studies; reported p-values 
are not adjusted for matching
a Defined as use of antihypertensive medication, systolic blood pressure ≥ 140  mmHg or diastolic blood 
pressure ≥ 90 mmHg
Characteristics Donors (n = 761) Matched nondonors (n = 1522) p value
Median (25–75p)/N (%) Median (25–75p)/N (%)
Age (years) 51.9 (42.8–60.1) 51.0 (37.8–57.9) p < 0.001
Gender (male) 318 (41.8) 636 (41.8) p = 1.000
Ethnicity (white) 681 (89.5) 1434 (94.2) p = 0.001
BMI (kg/m2) 25.9 (23.4–28.4) 25.5 (22.9–28.2) p = 0.176
Systolic blood pressure (mmHg) 130.0 (120.0–140.0) 125.5 (114.0–142.0) p = 0.010
Diastolic blood pressure (mmHg) 79.0 (70.0–85.0) 77.0 (70.0–85.0) p = 0.964
eGFR (ml/min/1.73 m2) 92.6 (79.8–103.8) 90.0 (78.9–102.3) p = 0.160
Serum glucose (mmol/l) 4.9 (4.3–5.4) 5.0 (4.7–5.4) p = 0.778
Pre-existing  hypertensiona 299 (39.3) 592 (38.9) p = 0.891
Pre-existing cardiovascular disease 13 (1.7) 28 (1.8) p = 0.956
Smoking 400 (52.6) 867 (57.0) p = 0.051
Alcohol use p = 0.560
 Never/rare 340 (44.7) 703 (46.2)
 ≤7 glasses/week 294 (38.6) 553 (36.3)
 >7 glasses/week 127 (16.7) 266 (17.5)
Education degree p = 0.011
 Primary 86 (11.3) 159 (10.4)
 Secondary 418 (54.9) 782 (51.4)
 Tertiary 257 (33.8) 581 (38.2)
Fig. 2  Overall eGFR levels over time: baseline and 7 years for non-
donors, and baseline, 1 year, and 8 years for donors
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The next step would be to predict the attributable risk for 
individual donors prior to donation [17].
A strength of our study is that, in addition to national 
registry data as used in other studies [15, 16], we collected 
individual donor and non-donor data on medical condi-
tions, physical examinations, laboratory tests, medication 
use, which were all manually verified in medical records 
and had minimal missing data (< 8%). Second, compared to 
previous studies [4, 9, 10, 15, 16, 18, 19] a strength of our 
study lies in the availability of repeated measurements of 
serum creatinine and albuminuria. Furthermore, compared 
to previous studies the current study design was optimized 
for donor and non-donor comparison. First, we matched on 
more baseline health characteristics than previous studies, 
including eGFR and comorbidity. Second, we adjusted for 
current lifestyle factors such as alcohol use and smoking. 
Finally, we performed propensity score matching which is 
suitable for observational data to balance both groups on a 
large number of covariates without losing a large number 
of observations,
Our study has a number of limitations. First, data on 
the type of antihypertensive medication was not available 
from our data sources for non-donors. Second, blood pres-
sure consisted of a single measurement in donors but on 
average 2–3 measurements in non-donors. Third, for SHIP 
participants, percutaneous coronary intervention and coro-
nary artery bypass surgery were not defined as cardiovas-
cular events. Fourth, EQ-5D scores were only available in 
the Rotterdam Study and SF-12 scores were only available 
in the SHIP. Finally, serum creatinine and eGFR are only 
estimates of kidney function that may deviate substantially 
from measured GFR in donors [37].
In conclusion, live kidney donors have reduced eGFR 
compared to non-donors, occurring in the first year after 
donation and stabilizing thereafter for at least 8 years with 
similar outcomes in terms of morbidity and mortality as 
non-donors. A lower risk of hypertension was found and 
no difference was found in cardiovascular risk. However, 
kidney function in donors may be further compromised 
with unforeseen circumstances. With the knowledge of this 
risk, albeit small, donors should be well-informed by the 
medical team before donation and be offered lifelong fol-
low-up thereafter. By monitoring kidney function, donors 
at risk may be identified at an early stage and adequate 
treatment may be offered. We consider this approach a 
prerequisite to legitimize a living kidney donor program.
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 BMI (kg/m2) 0.02 − 0.04; 0.07 p = 0.583
 New-onset diabetes 1.14 0.71; 1.84 p = 0.585
 New-onset  hypertensionb 0.45 0.33; 0.62 p < 0.001
 Cardiovascular event 1.06 0.64; 1.74 p = 0.823
 Cardiovascular mortality 0.13 0.01; 1.24 p = 0.077
 Overall mortality 0.06 0.05; 0.08 p < 0.001
 SF-12 physical component score − 1.36 − 2.38; − 0.33 p = 0.010
 SF-12 mental component score − 4.61 − 5.75; − 3.47 p < 0.001
 EQ-5D 0.06 0.05; 0.08 p < 0.001
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